| 1 | Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants显示文摘The global COVID-19 pandemic arising from SARS-CoV-2 has impacted many lives,gaining interest worldwide ever since it was first identified in December 2019.Till 2023,752 million cumulative cases and 6.8 million deaths were documented globally.COVID-19 has been rapidly evolving,affecting virus transmissibility and properties and contributing to increased disease severity.The Omicron is themost circulating variant of concern.Although success in its treatment has indicated progress in tackling the virus,limitations in delivering the current antiviral agents in battling emerging variants remain remarkable.With the latest advancements in nanotechnology for controlling infectious diseases,liposomes have the potential to counteract SARS-CoV-2 because of their ability to employ different targeting strategies,incorporating monoclonal antibodies for the active and passive targeting of infected patients.This review will present a concise summary of the possible strategies for utilizing immunoliposomes to improve current treatment against the occurrence of SARSCoV-2 and its variants. | Nur Dini Fatini Mohammad Faizal Nurul Afina Ramli Nur Najihah Izzati Mat Rani Nur Adania Shaibie Aartid Pattaporn Poonsawas Sunil K.Sharma Mohd Cairul Iqbal Mohd Amin | 2023 | Asian Journal of Pharmaceutical Sciences2023，18，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员